KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Progyny (PGNY) EBITDA (2018 - 2025)

Progyny (PGNY) has disclosed EBITDA for 8 consecutive years, with $15.2 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 3.58% to $15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $85.3 million through Dec 2025, up 26.42% year-over-year, with the annual reading at $85.3 million for FY2025, 26.42% up from the prior year.
  • EBITDA for Q4 2025 was $15.2 million at Progyny, down from $21.5 million in the prior quarter.
  • The five-year high for EBITDA was $24.4 million in Q2 2025, with the low at -$188000.0 in Q4 2021.
  • Average EBITDA over 5 years is $13.5 million, with a median of $14.4 million recorded in 2023.
  • The sharpest move saw EBITDA tumbled 116.19% in 2021, then soared 25981.03% in 2023.
  • Over 5 years, EBITDA stood at -$188000.0 in 2021, then skyrocketed by 1858.51% to $3.3 million in 2022, then surged by 317.42% to $13.8 million in 2023, then rose by 14.4% to $15.8 million in 2024, then fell by 3.58% to $15.2 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $15.2 million, $21.5 million, and $24.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.